Form 4: Candel Therapeutics Director Aguilar-Cordova Sells Shares

Director Estuardo Aguilar-Cordova reports selling shares of Candel Therapeutics (CADL) in multiple transactions.

Summary

• Estuardo Aguilar-Cordova, a director and 10% owner of Candel Therapeutics, sold shares of the company's stock.
• The sales occurred on October 11, 2024, October 14, 2024, and October 15, 2024.
• A total of 15,000 shares were sold on both October 11 and October 14 at prices of $6.05 and $6.02 respectively.
• An additional 10,412 shares were sold on October 15 at a price of $6.03.
• Following these transactions, Aguilar-Cordova directly owns 919,461 shares.
• Aguilar-Cordova also indirectly owns shares through the Estuardo Aguilar-Cordova 2020 Irrevocable Trust (2,074,942 shares), the Laura K. Aguilar 2020 Irrevocable Trust (2,013,100 shares), and the LKA 2022 revocable trust (874,943 shares).
• Laura K. Aguilar also indirectly owns shares jointly with Estuardo Aguilar-Cordova (171,335 shares).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the insider selling shares, which can create uncertainty among investors. However, the sales are not massive relative to total holdings.

Negatives

• A director selling shares could be perceived negatively by investors.

Risks

• Further sales by insiders could put downward pressure on the stock price.

Industry Context

Insider trading activity is always closely watched by investors as it can provide signals, though not always accurate, about the company's prospects.

Stakeholder Impact

• Shareholders may react to the news of insider selling.

Key Dates